-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KVHWkDMStArwxyX77C6+MRtyRUPNVi4swD1uF0DaQQ+wH6SyniHyM/ERY68gDXCn LH8f25FfxMoeeZ0E6AVjMA== 0001181431-08-001980.txt : 20080107 0001181431-08-001980.hdr.sgml : 20080107 20080107082042 ACCESSION NUMBER: 0001181431-08-001980 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080103 FILED AS OF DATE: 20080107 DATE AS OF CHANGE: 20080107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PANACOS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001040017 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 113238476 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 134 COOLIDGE AVE CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-1551 MAIL ADDRESS: STREET 1: 134 COOLIDGE AVE CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: V I TECHNOLOGIES INC DATE OF NAME CHANGE: 19980209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Henderson Jane CENTRAL INDEX KEY: 0001422304 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24241 FILM NUMBER: 08513768 BUSINESS ADDRESS: BUSINESS PHONE: (617) 926-1551 MAIL ADDRESS: STREET 1: C/O PANACOS PHARMACEUTICALS, INC. STREET 2: 134 COOLIDGE AVENUE CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 rrd186448.xml J HENDERSON FORM 4 JAN 3, 2008 X0202 4 2008-01-03 0 0001040017 PANACOS PHARMACEUTICALS, INC. PANC 0001422304 Henderson Jane C/O PANACOS PHARMACEUTICALS, INC. 134 COOLIDGE AVENUE WATERTOWN MA 02048 0 1 0 0 Chief Financial Officer, CBO Common Stock 2008-01-03 4 A 0 75000 0.00 A 75000 D Stock Option (Right to Buy) 0.77 2008-01-03 4 A 0 400000 0 A 2008-02-03 2018-01-03 Common Stock 400000 400000 D Options to purchase shares of the Company's common stock vest monthly, in 48 equal installments, beginning on February 3, 2008. Shares of common stock are currently unvested. Vesting, as specified in the applicable Restricted Stock Agreement, occurs at the earlier of (i)the dosing of the first patient in a Phase 3 trial or pivotal trial of a Panacos product candidate or (ii) January 3, 2011, the third anniversary of the grant date of the Restricted Stock. /s/ Jane Henderson 2008-01-07 -----END PRIVACY-ENHANCED MESSAGE-----